Sotac Pharmaceuticals Limited (NSE:SOTAC)

Market Cap	1.23B -11.9%
Revenue (ttm)	1.02B +1.3%
Net Income	57.67M -28.2%
EPS	5.22 -28.1%
Shares Out	11.05M
PE Ratio	21.26
Forward PE	n/a
Dividend	0.10 (0.09%)
Ex-Dividend Date	n/a

Volume	2,400
Open	111.00
Previous Close	111.00
Day's Range	111.00 - 111.00
52-Week Range	100.00 - 152.35
Beta	0.00
Analysts	n/a
Price Target	n/a
Earnings Date	May 26, 2026

About Sotac Pharmaceuticals

Sotac Pharmaceuticals Limited engages in the production, manufacturing, processing, and sale of various pharmaceutical products in India. Its therapeutic product portfolio includes anti-diabetic, anti-psychotic, vitamins, minerals, iron supplements, anti-cold, anti-allergic, dermatological solutions, antacid, anti-ulcerants, PPI, anti-emetics, cardiac, anti-hypertensives, analgesic, anti-pyretic, anti-inflammatory, anti-bacterial, anti-viral, general antibiotics, IP-lactams and non-IP-lactams, anti-fungal, and cephalosporin products. The compan...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2014
• Employees: 127
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SOTAC

Financial Performance

In fiscal year 2026, Sotac Pharmaceuticals's revenue was 1.02 billion, an increase of 1.33% compared to the previous year's 1.00 billion. Earnings were 57.67 million, a decrease of -28.16%.